Biogen Inc

NASDAQ:BIIB   3:59:59 PM EDT
239.29
+2.62 (+1.11%)
4:48:01 PM EDT: $239.25 -0.04 (-0.02%)
Products

FDA Approves Biogen's Aduhelm (Aducanumab) To Treat Patients With Alzheimer's Disease

Published: 06/07/2021 15:29 GMT
Biogen Inc (BIIB) - FDA’s Decision to Approve New Treatment for Alzheimer’s Disease.
Approved Aduhelm (aducanumab) to Treat Patients With Alzheimer’s Disease.
Requiring Biogen to Conduct a Post-approval Clinical Trial to Verify the Drug’s Clinical Benefit.
FDA Says If Aduhelm (aducanumab) Does Not Work As Intended, We Can Take Steps to Remove It From the Market.